Harmony Biosciences/HRMY

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Harmony Biosciences

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company. It is focused on developing and commercializing therapies for patients living with rare neurological diseases as well as patients living with other neurological diseases who have unmet medical needs. Its product, WAKIX (pitolisant), is a first-in-class molecule with a novel mechanism of action designed to enhance histamine signaling in the brain by binding to H3 receptors. Its WAKIX is developed for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy and treatment of cataplexy in adult patients with narcolepsy. It also provides HBS-102, an investigational compound, which is a melanin-concentrating hormone receptor 1 (MCHR1) antagonist that targets MCH neurons in the brain. It also develops ZYN002, a pharmaceutically manufactured synthetic cannabidiol. It is also focused on the rare epilepsy franchise in its expanding late-stage pipeline of CNS assets: EPX-100 and EPX-200.

Ticker

HRMY

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Jeffrey Dayno

Employees

246

Headquarters

Plymouth meeting, United States

HRMY Metrics

BasicAdvanced
$1.7B
Market cap
12.69
P/E ratio
$2.32
EPS
0.72
Beta
-
Dividend rate
$1.7B
0.71977
$39.27
$18.61
407K
3.109
3.071
33.954
36.864
9.192
31.38%
17.63%
28.73%
20.83%
12.692
2.704
3.24
4.345
8.041
30.92%
-25.08%
53.88%

What the Analysts think about HRMY

Analyst Ratings

Majority rating from 7 analysts.
Buy

HRMY Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
24.77% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$155M
-8.19%
Net income
$38M
43.98%
Profit margin
24.77%
56.87%

HRMY Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 10.87%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$0.56
$0.63
$0.45
$0.67
-
Expected
$0.63
$0.65
$0.48
$0.60
$0.01
Surprise
-11.46%
-3.08%
-6.01%
10.87%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Harmony Biosciences stock?

Harmony Biosciences (HRMY) has a market cap of $1.7B as of June 19, 2024.

What is the P/E ratio for Harmony Biosciences stock?

The price to earnings (P/E) ratio for Harmony Biosciences (HRMY) stock is 12.69 as of June 19, 2024.

Does Harmony Biosciences stock pay dividends?

No, Harmony Biosciences (HRMY) stock does not pay dividends to its shareholders as of June 19, 2024.

When is the next Harmony Biosciences dividend payment date?

Harmony Biosciences (HRMY) stock does not pay dividends to its shareholders.

What is the beta indicator for Harmony Biosciences?

Harmony Biosciences (HRMY) has a beta rating of 0.72. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Harmony Biosciences stock price target?

The target price for Harmony Biosciences (HRMY) stock is $43, which is NaN% below the current price of $. This is an average based on projections from 7 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Harmony Biosciences stock

Buy or sell Harmony Biosciences stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing